



IPCS 2026

Poster Totem Display

Opens on Tuesday 28 April at 16:00

Room B2 - First floor - Convention Centre

IPCS 2026 is organised by the Foundation for the Institute of Oncology Research (IOR) in collaboration with APC Society, with the support of



**Title and
Presenter**

Category: Molecular Biology and Genetics

Endocrine disruptors promote protein synthesis and secretion of extracellular matrix component proteins: from cohort to bench

Harmonizing the Prostate Cancer Transcriptome: A Unified Nextflow Pipeline for Integrating Public RNA-seq and FFPE Archives via Regression Modeling

ERF-202 isoform is a tumor suppressor in prostate cancer

Delineating cell states and cellular interactions in locally-advanced treatment-naïve prostate cancer

A t-NEPC model to determine potential therapeutic targets

Molecular Mechanisms of IGFBP-7 in Stem Cell Senescence: A Multi- Dimensional Regulator of Senescence-Associated Secretory Phenotype (SASP)

Prevalence of PIK3CA/AKT1/PTEN alterations in TMB-high mCRPC

Decoding the RNA-Protein Interactome of the Androgen Receptor in Prostate Cancer Plasticity and Castration Resistance

Prostate Cancer Cell-Derived Extracellular Vesicles Reprogram Adipocytes into a Lipolytic Tumor-Supporting Phenotype

Loss of LXR enhances tumor growth in preclinical prostate cancer models: role of immune system

Investigating the role of novel transcripts from the MYCN locus in driving treatment emergent neuroendocrine prostate cancer

Category: Diagnostics & Biomarkers

Androgen Deprivation Therapy-Induced Acceleration of Aging and Its Early Prediction in Prostate Cancer: A Multi-Omics Prospective Cohort and Mechanistic Study

Associations of 2923 plasma proteins with prostate cancer in prospective cohort study integrating machine-learning and genetic analysis

DP3: an observational cohort study protocol collecting clinical, lifestyle, and multi-omics data for novel prostate cancer biomarker identification

The role of PSMA-PET/CT for stratification and selection of patients eligible for focal therapy in early non-metastatic prostate cancer

Health outcomes of androgen deprivation therapy (ADT) and androgen receptor signaling inhibitors (ARSI) in prostate cancer: An umbrella meta-analysis

PSMA-PET as a Biomarker for Patient Selection in Metastasis-Directed Radiotherapy for Oligometastatic Prostate Cancer

Neutrophil-to-lymphocyte ratio as early predictive biomarker of ^{177}Lu -PSMA-617 radioligand therapy response in metastatic castrate resistant prostate cancer patients

Pathogen signatures in urine: a non-invasive approach to discriminate prostate cancer among men recalled for biopsy

Interplay Between TSPAN8 and Phosphatases in Prostate Cancer

Diagnostic Challenges and Emerging Biomarkers in Prostate Cancer: An Indian Perspective

FOXP3 and P53 expression in prostate carcinoma and their correlation with histological grades among prostate carcinoma patients at uganda cancer institute

Category: Therapeutic resistance

Minor intron splicing : A vulnerability in RB1-E2F altered prostate cancer

Patient-derived organoids for castration-resistant Prostate cancer personalized medicine

Stromal Expression and Regulation of the GR/AR Target MAO-A During Prostate Cancer Progression and Chemotherapeutic Treatment

Identification of evolutive biomarkers and mechanisms underlying treatment resistance in prostate cancer

Category: Novel treatments

Cell fate reprogramming by ESE3/EHF gene delivery in prostate cancer

Comparative Oncological Outcomes of Radical Prostatectomy versus Radiotherapy in High-Risk Localized Prostate Cancer: A Systematic Review and Meta-analysis

Category: Theranostics

Efficacy, Safety, and Dosimetric Predictors of Lu-177 PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer

Category: Clinical Trials

Risk-adapted Stereotactic Body Radiotherapy for Prostate Cancer: An Institutional Quality Control Analysis